MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS-Reference-Cited by-同舟云学术

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

Published:1998-10 Issue:4 Volume:160 Page:1220-1229
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

OH WILLIAM K.¹,KANTOFF PHILIP W.¹

Affiliation:

1. From the Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference107 articles.

1. Cancer statistics, 1998;Landis;Cancer J. Clin.,1998

2. Studies on prostatic cancer;Huggins;II. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg.,1941

3. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma;Crawford;New Engl. J. Med.,1989

4. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs;Raghavan;Sem. Oncol.,1988

5. Hormone-refractory (D3) prostate cancer: refining the concept;Scher;Urology,1995

Cited by 218 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Efficacy and Safety of a Low Relative Dose Intensity of Cabazitaxel in Patients With Metastatic Castration-resistant Prostate Cancer;Anticancer Research;2023-09-29

2. Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications;Advances in Experimental Medicine and Biology;2022

3. Systemic Triple Therapy in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored?;Cancers;2021-12-21

4. Papel del índice neutrófilo/linfocito en pacientes con cáncer de próstata resistente a castración metastásicos tratados en primera línea con abiraterona;Actas Urológicas Españolas;2020-04

5. Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone;Actas Urológicas Españolas (English Edition);2020-04